16 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]
- RxCUI
- 2627659
- RxNorm name
- 16 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]
- Display name
- 16 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]
- Full name
- 16 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:57
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761268 | Vegzelma | bevacizumab-adcd | 351(k) Biosimilar | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vegzelma | BEVACIZUMAB-ADCD | CELLTRION USA, Inc. | 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe | 2025-05-08 | Warnings, Adverse reactions | 2627659 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe | 16 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma] | SBD | 4 | These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b | 20250508 |
| 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe | Vegzelma 400 MG in 16 ML Injection | PSN | 4 | These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b | 20250508 |
| 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe | 16 ML Vegzelma 25 MG/ML Injection | SY | 4 | These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b | 20250508 |
| 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe | Vegzelma 400 MG per 16 ML Injection | SY | 4 | These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b | 20250508 |